Shares of ProKidney Corp. PROK, +9.57% rallied about 29% in premarket trading on Wednesday, the day after the company said preliminary data from a Phase 2 study found that the company’s investigational renal autologous cell therapy treatment can delay the need for dialysis in some patients with chronic kidney disease. The study was published Jan. 4 in the journal Blood Purification; the company issued a news release about the study on Tuesday. ProKidney’s stock is down 22.3% for the past year, while the S&P 500 SPX, +0.70% has declined 16.1%.
Balanced News: Sample Page Title
Our 'quick read' news summary
Read different perspectives from these news sources
Searching for related articles, please check back here later!
More top reads from Balanced News Summary
- Advertisment -